| CAS | 229305-39-9 |
| Sequence | H-D-Glu(Trp-OH)-OH |
| Sequence Single | e(W) |
| Molecular Formula | C16H19N3O5 |
| Molecular Weight | 333.34 |
| Synonyms | H-γ-D-Glu-Trp-OH, Golotimod, Bestim |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Di- and Tripeptides|Immunomodulating Agents |
| Description | H-D-Glu(Trp-OH)-OH also called H-γ-D-Glu-Trp-OH, Golotimod, Bestim, an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). |
| References | 1. Peptide exosite inhibitors of factor VIIa as anticoagulants. M.S.Dennis et al., Nature, 404, 465 (2000) 2. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Rose WA 2nd, et al. Int J Antimicrob Agents. 2008 Sep;32(3):262-6. 3. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Geiger JL, et al. Oral Oncol. 2016 May;56:84-92. 4. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Watkins B, et al. Oral Dis. 2010 Oct;16(7):655-60. |